Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Treasury Shares (2020 - 2025)

Arcutis Biotherapeutics has reported Treasury Shares over the past 6 years, most recently at $6.0 million for Q4 2025.

  • Quarterly results put Treasury Shares at $6.0 million for Q4 2025, down 0.79% from a year ago — trailing twelve months through Dec 2025 was $6.0 million (down 0.79% YoY), and the annual figure for FY2025 was $6.0 million, down 0.79%.
  • Treasury Shares for Q4 2025 was $6.0 million at Arcutis Biotherapeutics, down from $6.2 million in the prior quarter.
  • Over the last five years, Treasury Shares for ARQT hit a ceiling of $7.2 million in Q1 2025 and a floor of $310068.0 in Q1 2021.
  • Median Treasury Shares over the past 5 years was $2.9 million (2023), compared with a mean of $3.5 million.
  • Biggest five-year swings in Treasury Shares: soared 370.33% in 2022 and later dropped 4.59% in 2025.
  • Arcutis Biotherapeutics' Treasury Shares stood at $335196.0 in 2021, then soared by 370.33% to $1.6 million in 2022, then soared by 85.83% to $2.9 million in 2023, then surged by 106.69% to $6.1 million in 2024, then fell by 0.79% to $6.0 million in 2025.
  • The last three reported values for Treasury Shares were $6.0 million (Q4 2025), $6.2 million (Q3 2025), and $6.6 million (Q2 2025) per Business Quant data.